Allogene Therapeutics (ALLO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Allogene Therapeutics (ALLO) is Neutral.

The composite score behind that read is -0.08, weighing +0.23 of bullish evidence against -0.31 bearish.

Allogene Therapeutics last closed at $1.46, +4.29% on the session.

Against the IVW growth benchmark the position is +3.49% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

10 graded predictions for ALLO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Allogene Therapeutics in the 18th percentile on return on equity, where 100 is best.

Allogene Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $483.69M.

StockMap tracks Allogene Therapeutics as the 180th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Allogene Therapeutics ranks 187th of 381 in the group, against a group median of -0.08.